Idera in trial, supply pact with Bristol-Myers

In a regulatory filing earlier, Idera Pharmaceuticals (IDRA) reported that the company entered into a clinical trial collaboration and supply agreement on May 18 with Bristol-Myers Squibb (BMY) to clinically evaluate the combination of the company’s TLR-9 agonist IMO-2125 with BMS’s therapy Yervoy. Under the Collaboration and Supply Agreement, the Company will sponsor, fund and conduct the Company’s ongoing global, open-label, multi-center Phase 3 clinical trial of tilsotolimod in combination with Yervoy in accordance with an agreed-upon protocol. Under the collaboration and supply agreement, BMS has granted to the company a non-exclusive, non-transferrable, royalty-free license, with a right to sublicense, under its intellectual property to use Yervoy in the trial and has agreed to manufacture and supply Yervoy, at its cost and for no charge to the company, for use in the trial.

https://bit.ly/2s94SH8